Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT

Sponsor
UNC Lineberger Comprehensive Cancer Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05937659
Collaborator
(none)
20
1
19
1.1

Study Details

Study Description

Brief Summary

This study will assess the feasibility of incorporating biometric data via wearable health technology (WHT) into the radiation oncology (RO) clinic workflow for patients receiving concurrent radiation therapy and systemic therapy (CRT) for cancer. The investigators hypothesize that a practical workflow could be created within a busy community RO practice that will allow providers and patients to readily appreciate physiologic declines during concurrent CRT.

Subjects will be asked to wear a device as part of this study that will collect their biometric data (heart rate, number of steps taken per day, etc) called a WHT device throughout their treatment and for 4 weeks afterward. Subjects will be asked to upload the data from their devices onto the computers in the clinic for the assessment.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Incorporating Biometric Data Evaluation for Patients Receiving Concurrent Chemotherapy and Radiation Therapy
    Anticipated Study Start Date :
    Aug 15, 2023
    Anticipated Primary Completion Date :
    Mar 15, 2025
    Anticipated Study Completion Date :
    Mar 15, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    Biometric Data Collection

    Adult subjects with cancer and prescribed concurrent systemic therapy and radiation therapy and enrolled in the study.

    Outcome Measures

    Primary Outcome Measures

    1. The rate of technology adoption [Up to 12 weeks]

      The rate of technology adoption will be quantified as the fraction of subjects who successfully download their WHT data into the research databases in the radiation oncology clinic. Success, on a subject-specific basis, will be defined as their reporting any of their WHT biometric data on >40% of eligible days.

    Secondary Outcome Measures

    1. Provider perception of the utility [Up to 12 weeks]

      The physician's and nurse's subjective assessment of the utility of having the subject's wearable health technology data such as enhanced dietary or hydration counseling, supportive medication alteration, and/or intravenous fluid hydration will be quantified, using a survey.

    2. Subject perception of the utility [Up to 12 weeks]

      The subjects' responses to the utility of wearable health technology data will be quantified using surveys.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    Inclusion Criteria In order to participate in this study a subject must meet all of the eligibility criteria outlined below.

    Subjects

    1. All genders aged ≥ 18 years of age.

    2. English-speakers

    3. Able to understand and cooperate with study procedures.

    4. Signed and dated informed consent.

    5. Subjects being seen at Novant-New Hanover Regional Medical Center for diagnosis and management of cancer.

    6. Subjects prescribed to receive concurrent radiation therapy and systemic therapy either definitively or postoperatively.

    7. Signed and dated HIPAA authorization for the release of personal health information.

    Providers

    1. All genders aged ≥ 18 years of age.

    2. English speakers.

    3. Able to understand and cooperate with study procedures.

    4. Signed and dated informed consent.

    Exclusion Criteria Both Subjects and care providers

    1. Has dementia, altered mental status, or any psychiatric or co-morbid condition prohibiting the understanding or rending of informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Novant Health Cancer Institute Radiation Oncology Wilmington North Carolina United States 28401

    Sponsors and Collaborators

    • UNC Lineberger Comprehensive Cancer Center

    Investigators

    • Principal Investigator: Lukasz Mazur, MD, UNC Lineberger Comprehensive Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    UNC Lineberger Comprehensive Cancer Center
    ClinicalTrials.gov Identifier:
    NCT05937659
    Other Study ID Numbers:
    • LCCC2237
    First Posted:
    Jul 10, 2023
    Last Update Posted:
    Jul 11, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by UNC Lineberger Comprehensive Cancer Center

    Study Results

    No Results Posted as of Jul 11, 2023